September 18, 2025
Pfizer and Arvinas Abandon Commercialization of PROTAC Inhibitor, Triggering Layoffs and Pipeline Refocus
Pfizer; Arvinas; PROTAC; vepdegestrant; layoffs; out-licensing; FDA; breast cancer; oncology; CDK inhibitors
Genentech Names Zoë Harris Lazarre as New Chief Marketing Officer as Erica Taylor Moves to Roche Role
Genentech; Chief Marketing Officer; Erica Taylor; Zoë Harris Lazarre; Roche; leadership change; pharmaceutical marketing; biotech industry
Lilly’s Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion
Mounjaro; tirzepatide; type 2 diabetes; children; adolescents; SURPASS-PEDS; A1C reduction; BMI reduction; clinical trial; Eli Lilly
VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery
VectorY Therapeutics; Shape Therapeutics; SHP-DB1; adeno-associated virus (AAV) capsid; brain-penetrant delivery; gene therapy; neurodegenerative diseases; Huntington’s disease; Alzheimer’s disease; biobucks; pipeline; milestone payments; vectorized antibodies
bluebird bio Rebrands as Genetix Biotherapeutics Following Private Equity Buyout
bluebird bio; Genetix Biotherapeutics; private equity buyout; Carlyle; SK Capital Partners; gene therapy; rebranding; FDA-approved therapies; David Meek; sickle cell disease; β-thalassemia; cerebral adrenoleukodystrophy; commercial execution; manufacturing investment
Novo Nordisk Awaits FDA Decision on Oral Wegovy Pill for Obesity
Novo Nordisk; Wegovy; oral semaglutide; FDA approval; obesity treatment; GLP-1 pill; weight loss; cardiovascular risk
GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing
GSK; $30 billion investment; U.S. expansion; R&D; manufacturing; biopharma; supply chain; advanced digital technologies
ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot
ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership
Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey
Novo Nordisk; Bristol Myers Squibb; layoffs; New Jersey; pharmaceutical industry; restructuring; job cuts; Ozempic; Wegovy; workforce reduction
Priovant Announces Successful Phase III Results for Brepocitinib in Dermatomyositis (VALOR Study)
Priovant; Roivant; brepocitinib; Phase III; VALOR study; dermatomyositis; clinical trial; Total Improvement Score; TIS; steroid reduction; cutaneous remission; NDA filing